Hepatitis B


​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.  

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight
  • Genotype
  • Fibrosis Score

LABS

  • CBC
  • ALT / AST
  • HBV Viral Load
  • Serum Creatinine
  • eGFR
  • HbA1c
  • HBeAg, HBeAb
  • APRI score
  • Bone Density

PRIOR HISTORY

  • Prior Treatment Status
  • Prior Treatment Regimen
  • Duration of Therapy
  • Reason for Failure
  • Prior Transplant
  • Smoking Status
  • Illicit Drug Use

COMORBIDS

  • HIV Coinfection
  • Anxiety
  • Depression
  • Hypertension
  • Diabetes
  • Chronic Kidney Disease
  • Hyperlipidemia
  • Hemodialysis

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Gaps in Therapy

Publications


2018

Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice; Real‐World Evidence from the Trio Network

Treatment of Hepatitis B in the Us; Real‐World Evidence from the Trio Network